Table 2 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy complication, using G0/G2 chromosomal assay
| Reference | Marker | Sample size | Cell type | Radiation dose | Result |
|---|---|---|---|---|---|
| Breast cancer | |||||
| Ryabchenk et al. 2012 [148] | G0 and G2 chromosomal assay | 1. BC cases (37) | Lymphocyte | G0 assay | G0 assay & G2 assay |
| 2. Healthy controls (44) | 1.5 Gy | Spontaneous RS | |||
| X-rays | BC cases ↔ Healthy controls | ||||
| G2 assay | G0 assay & G2 assay | ||||
| 0.5 Gy | RS after radiation | ||||
| X-rays | BC cases > Healthy controls | ||||
| Bryant et al. 2012 [151] | G2 chromosomal assay | 1. BC cases (89) | Lymphocyte | 0.4 Gy | RS after radiation |
| 2. Healthy controls (96) | γ-rays | BC cases > Healthy controls | |||
| Wang et al. (2012) [152] | G2 chromosomal assay | 1. BC cases (515) | Lymphocyte | 1.5 Gy | non-Hispanic White |
| 2. Healthy controls (402) | γ-rays | BC cases > Healthy control | |||
| Mexican American | |||||
| BC cases > Healthy control | |||||
| African Americans | |||||
| BC cases ↔ Healthy controls | |||||
| Poggioli et al. 2010 [150] | G0 & G2 chromosomal assay | 1. BC cases (23) | Lymphocyte | G2 assay | G0 assay & G2 assay |
| 2. Healthy controls (23) | 0.4 Gy | Spontaneous RS | |||
| X-rays | BC cases ↔ Healthy controls | ||||
| G0 assay | G0 assay & G2 assay | ||||
| 2 Gy | RS after radiation | ||||
| X-rays | BC cases > Healthy controls | ||||
| G2 assay could be more appropriate to define the individual RS if compare with G0 assay | |||||
| Howe et al. 2005 [149] | G2 chromosomal assay | 1. BC cases (27) | Lymphocyte | 0.5 Gy | RS after radiation |
| 2. Healthy controls (14) | γ-rays | BC cases > Healthy controls | |||
| Riches et al. 2001 [147] | G2 chromosomal assay | 1. BC cases (65) | Lymphocyte | 0.4 Gy | RS after radiation |
| 2. Healthy controls (66) | γ-rays | BC cases > Healthy controls | |||
| Scott et al. 1999 [135] | G2 chromosomal assay | 1. BC cases (135) | Lymphocyte | 0.5 Gy | Spontaneous RS |
| 2. Healthy controls (105) | X-rays | Healthy control ↔ BC cases | |||
| RS after radiation | |||||
| BC cases > Healthy controls | |||||
| BRCA1/2 mutation | |||||
| Ernestos et al. 2010 [153] | G2 chromosomal assay | 1. BC cases with BRCA1/2 mutation (15) | Lymphocyte | 1 Gy | RS after radiation |
| 2. Healthy BRCA1/2 mutation carriers (5) | γ-rays | BC with BRCA1/2 mutation > Healthy controls | |||
| 3. Healthy controls W/O familial history of cancer (21) | Healthy BRCA1/2 mutation carriers > Healthy controls | ||||
| Baeyens et al (2002) [139] | G2 chromosomal assay | 1. BC cases with BRCA1/2 mutation (20) | Lymphocyte | 0.4 Gy | Spontaneous RS |
| A. BRCA1(11) | γ-rays | No difference across all groups | |||
| B. BRCA2 (9) | RS after radiation | ||||
| 2. Healthy relatives with BRCA mutation (12) | BC with BRCA1 mutation ↔ BC W/O BRCA mutation ↔ healthy controls | ||||
| A. BRCA1 (6) | BC with BRCA2 mutation > healthy controls | ||||
| B. BRCA2 (6) | Healthy relatives with and W/O a BRCA1 mutation ↔ healthy controls | ||||
| 3. Healthy relatives W/O BRCA mutation (10) | |||||
| A. of BRCA1 (5) | |||||
| B. of BRCA2 (5) | |||||
| 4. BC cases W/O BRCA mutation (78) | |||||
| 5. Healthy controls (58) | |||||
| Radiotherapy complications | |||||
| Finnon et al. 2012 [143] | G2 chromosomal assay | 1. BC cases with marked reaction (31) | Lymphocyte | 3.5 Gy | RS after radiation |
| 2. BC cases with mild late adverse reaction (28) | X-rays | Marked reaction ↔ Mild late adverse reaction | |||
| Barber et al. 2000 [134] | G2 chromosomal assay |
HDR Acute reactions before radiotherapy (116) Late reactions, 8-14 years after radiotherapy (47) LDR Acute reactions before radiotherapy (73) Late reactions, 8-14 years after radiotherapy (26) | Lymphocyte | HDR | HDR |
| 3.5 Gy γ-rays (dose rate 1.0 Gy min-1) | RS after radiation | ||||
| Acute reactions before radiotherapy ↔ 8-14 years after radiotherapy | |||||
| LDR | |||||
| 3.5 Gy γ-rays (dose rate 0.15 Gy min-1) | LDR | ||||
| RS after radiation | |||||
| Acute reactions before radiotherapy ↔ 8-14 years after radiotherapy | |||||